AstraZeneca wins FDA nod for SGLT2 combo diabetes med; Novo hiring in NH for new hemophilia factory;

@FiercePharma: CEO-hunting Sanofi tried to tempt AstraZeneca's Soriot: Bloomberg. Article | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: Sanofi says it doesn't not know why its flu strains grew slowly, holding up vax deliveries in U.S. Article | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Pfizer beats out Novartis with FDA MenB nod. FierceVaccines article | Follow @CarlyHFierce

> AstraZeneca ($AZN) won the FDA's blessing for its combination diabetes treatment Xigduo, which encompasses its new SGLT2 drug dapagliflozin and the standard therapy metformin. Release

> Novo Nordisk ($NVO) is staffing up in New Hampshire for a new facility that will turn out hemophilia treatments for the U.S. market. Release

> India's Cipla launched a cheaper copy of the Novartis ($NVS) respiratory drug Onbrez in its home market, and has asked the government to pull the Swiss drugmaker's patents on the product. Report

> AMAG Pharmaceuticals ($AMAG) reported $25.5 million in third-quarter revenue, most of which came from its anemia drug Feraheme. Report

> Fujifilm backed away from estimating how profitably its flu-fighting drug Avigan might be; the company is expanding production of the drug, which is earmarked to fight Ebola. Report

Medical Device News

@FierceMedDev: Ken Drazan of JNJ Innovation talks future of med tech. Editor's Corner | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: Rating agencies likely to cut Medtronic's credit rating due to looming merger with Covidien. Story | Follow @VarunSaxena2

@EmilyWFierce: ICYMI: Check out @FierceMedDev's list of the most influential women in the med tech industry here. Feature | Follow @EmilyWFierce

@MichaelGFierce: @HarvardResearch team uses stem cells to deliver toxic doses to #cancer cells. More | Follow @MichaelGFierce

> Chinese government urges hospitals to buy local devices. News

> Nintendo developing cloud-based sleep-monitoring device amid market growth. Story

> GE Healthcare opens first health tech incubator. Article

Biotech News

@FierceBiotech: ICYMI earlier this month, check out this year's Women in Biotech, featuring women at the top of their field. Feature | Follow @FierceBiotech

@JohnCFierce: If $SNY's board did turn to Soriot ($AZN) to try and recruit him for CEO, it shows they don't really know what they're doing. | Follow @JohnCFierce

@DamianFierce: Six of Cleveland Clinic's Top 10 Medical Innovations are drugs, and here's a bunch of words on them. Article | Follow @DamianFierce

@EmilyMFierce: Good read on Sarepta and the issue of compassionate use. More from Bloomberg BusinessWeek | Follow @EmilyMFierce

> Little Cortendo gains $11M for late-stage Cushing's study, hatches U.S. IPO plans. Story

> Bristol-Myers' nivolumab impresses once again--this time in crucial lung cancer study. Report

> Novo Nordisk walks back some U.S. optimism for its next-gen insulin. Article

Vaccines News

> South African trial renews hopes in failed HIV vaccine combo. More

> Dendreon's Provenge at the center of CMS insider trading probe. Item

> Pfizer beats out Novartis with FDA MenB nod. Story

> Ebola update: Novavax testing nanoparticle jab, Glaxo gets EMA's advice. More

> Novartis officially bows out of vaccines with flu sale to CSL. Article

Pharma Manufacturing News

> Turkish man sent to prison for smuggling fake Avastin into U.S. Item

> Novo hiring 90 workers for its new plant in New Hampshire. News

> More heat applied to Genentech CEO for supply-chain decision on cancer drugs. Report

> Lilly offers behind-the-scenes look at its decade-long tech transfer for TB drugs. Story

> Serum Institute of India to invest $160M in new plant. Article

And Finally... Google ($GOOG) is developing a pill to sniff out cancer, heart disease. Report

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.